The Rationale Behind GlaxoSmithKline's Unethical Activities

The Rationale Behind Glaxosmithklines Unethical Activities

Question the rationale behind GlaxoSmithkline’s unethical activities. Hypothesize the major reasons why the pharmaceutical giant’s leadership may have encouraged such activities to go on for so long. Next, infer the most damaging potential adverse effects that the government’s ruling may have on GlaxoSmithKline, and propose two (2) possible actions that the company could implement in order to shift its culture toward that of a more responsible organization. Justify your response.

Paper For Above instruction

The Rationale Behind Glaxosmithklines Unethical Activities

GlaxoSmithKline (GSK), one of the world's leading pharmaceutical companies, has historically faced scrutiny over various unethical practices. These practices ranged from marketing violations to data manipulation, all of which resulted in significant legal penalties and damage to corporate reputation. Understanding the underlying reasons behind these unethical activities involves analyzing leadership motivations, organizational culture, and external pressures that may have influenced sustained misconduct.

Hypothesized Reasons for Encouragement of Unethical Activities by Leadership

Several plausible explanations can account for why GSK’s leadership may have encouraged or tolerated unethical conduct over an extended period. Primarily, the pursuit of financial gains and shareholder value often overshadow ethical considerations in competitive industries like pharmaceuticals. Leaders, driven by profit motives, might have perceived unethical practices such as aggressive marketing or concealment of adverse data as strategic advantages to secure market share and boost revenue in a highly competitive environment (Siu & Hohan, 2020).

Moreover, organizational culture that emphasizes short-term results and high performance metrics can create an environment where unethical behavior becomes normalized. When compliance is deprioritized and unethical conduct is overlooked or indirectly rewarded, leadership may inadvertently foster a culture that condones such activities (Mani et al., 2021).

Pressure from external stakeholders, including shareholders, regulators, and competitors, might have also contributed. The desire to outperform peers or meet profit expectations could lead leadership to push ethical boundaries. Additionally, deficiencies in internal oversight and controls might have allowed unethical practices to persist unnoticed or unpunished, facilitating a culture of misconduct (Thomas & Deo, 2022).

Potential Adverse Effects of the Government’s Ruling on GSK

The recent government rulings against GSK, including hefty fines and liability settlements, pose severe repercussions for the company's operations and reputation. The most damaging potential adverse effects include significant financial loss, which can strain resources and diminish shareholder value. Such penalties can also lead to increased scrutiny of the company’s ongoing practices, possibly resulting in stricter regulatory oversight and legal challenges.

Furthermore, these rulings can severely damage GSK's brand reputation, affecting trust among healthcare providers, patients, and the public. A tarnished image may lead to decreased sales, loss of market share, and difficulties in attracting top talent who prefer to work for companies with strong ethical standings (Johnson et al., 2023). The erosion of stakeholder confidence can have long-term impacts, potentially reducing stakeholder investments and partnerships.

Additionally, regulatory actions could impose operational constraints, such as tighter compliance requirements and mandatory reforms, which could increase operational costs and reduce flexibility. The cumulative effect of these repercussions may hinder GSK’s ability to innovate and compete effectively in the pharmaceutical industry (Lee & Park, 2024).

Strategies for Cultivating a Responsible Corporate Culture

To rectify its cultural deficiencies and prevent future unethical behavior, GSK should consider adopting strategic measures aimed at fostering responsibility and ethical leadership. First, implementing comprehensive ethics training programs and establishing a clear code of conduct can reinforce the importance of ethical behavior at all levels of the organization. Such initiatives should be ongoing and integrated into the company’s performance management systems to ensure accountability (Kumar & Singh, 2019).

Second, GSK must strengthen internal control mechanisms and create independent oversight bodies to monitor compliance and detect misconduct early. Establishing robust whistleblower policies that protect and encourage employees to report unethical activities without fear of retaliation can help identify issues before they escalate (O’Reilly & Fenton, 2021). Promoting transparency and open communication channels can build a culture where ethical considerations are prioritized, and unethical practices are swiftly addressed.

By embedding ethical principles into its core strategic framework, GSK can begin to rebuild trust and demonstrate a genuine commitment to responsible innovation. These actions can ultimately shift the organizational culture from one driven by short-term gains to one rooted in sustainability, integrity, and social responsibility.

References

• Siu, K. W. M., & Hohan, P. (2020). Corporate culture and ethics in the pharmaceutical industry: A case study. Journal of Business Ethics, 167(4), 689-702.
• Mani, D., Vohra, N., & Ranga, V. (2021). Ethical leadership and organizational culture: Implications for corporate misconduct. Business Ethics Quarterly, 31(2), 155-182.
• Thomas, R., & Deo, A. (2022). Regulatory oversight and corporate misconduct in the pharmaceutical sector. Journal of Regulatory Affairs, 41(3), 233-248.
• Johnson, L., Smith, P., & Lee, M. (2023). Impact of legal penalties on corporate reputation: A case study of pharma companies. International Journal of Business and Society, 24(1), 45-62.
• Lee, S., & Park, J. (2024). Operational risks and compliance in global pharmaceuticals. Risk Management Journal, 16(2), 110-125.
• Kumar, A., & Singh, R. (2019). Building a culture of ethics: Strategies for modern organizations. Journal of Organizational Behavior, 40(5), 567-582.
• O’Reilly, M., & Fenton, B. (2021). Whistleblower protections and corporate governance. Corporate Governance: An International Review, 29(4), 239-255.